- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 89,000 | 31.05.24 14:01:50 | +1,000 | +1,14% | 89,660 | 89,840 | 88,000 | 88,000 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 898,400 | 31.05.24 08:14:27 | +17,200 | +1,95% | 891,600 | 897,400 | 898,400 | 881,200 |
